Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.

Leung TS, Law EH.

Drug Des Devel Ther. 2015 Jul 9;9:3557-69. doi: 10.2147/DDDT.S70299. eCollection 2015. Review.

2.

Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery.

Du W, Zhao C, Wang J, Liu J, Shen B, Zheng Y.

J Orthop Surg Res. 2015 May 23;10:78. doi: 10.1186/s13018-015-0223-7.

3.

Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis.

Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M.

Circulation. 2015 Jul 21;132(3):194-204. doi: 10.1161/CIRCULATIONAHA.114.013267. Epub 2015 May 20. Review.

4.

Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.

Fermann GJ, Erkens PM, Prins MH, Wells PS, Pap ÁF, Lensing AW.

Acad Emerg Med. 2015 Mar;22(3):299-307. doi: 10.1111/acem.12615. Epub 2015 Feb 25.

5.

The role of factor Xa inhibitors in venous thromboembolism treatment.

Cabral KP, Ansell JE.

Vasc Health Risk Manag. 2015 Jan 30;11:117-23. doi: 10.2147/VHRM.S39726. eCollection 2015. Review.

6.

Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study.

Caldeira D, Cruz I, Morgado G, Stuart B, Gomes C, Martins C, João I, Pereira H.

BMC Res Notes. 2014 Dec 9;7:891. doi: 10.1186/1756-0500-7-891.

7.

Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.

Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E.

Vasc Health Risk Manag. 2014 Nov 7;10:627-39. doi: 10.2147/VHRM.S50543. eCollection 2014. Review.

8.

Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.

Douketis J, Bell AD, Eikelboom J, Liew A.

Can Fam Physician. 2014 Nov;60(11):997-1001.

9.

Concurrent pulmonary thrombosis with systemic embolism: a case report.

Xie XJ, Jiang JB, Jiang J, Wang JA.

J Zhejiang Univ Sci B. 2014 Sep;15(9):838-44. doi: 10.1631/jzus.B1400209.

10.

Management of acute stroke in patients taking novel oral anticoagulants.

Hankey GJ, Norrving B, Hacke W, Steiner T.

Int J Stroke. 2014 Jul;9(5):627-32. doi: 10.1111/ijs.12295. Epub 2014 Jun 2. Review.

11.

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

Beyer-Westendorf J, Förster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, Köhler C, Werth S, Sahin K, Tittl L, Hänsel U, Weiss N.

Blood. 2014 Aug 7;124(6):955-62. doi: 10.1182/blood-2014-03-563577. Epub 2014 May 23.

12.

Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.

Cohen AT, Imfeld S, Rider T.

Adv Ther. 2014 May;31(5):473-93. doi: 10.1007/s12325-014-0119-7. Epub 2014 May 13. Review.

13.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

14.

Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.

Harel Z, Sholzberg M, Shah PS, Pavenski K, Harel S, Wald R, Bell CM, Perl J.

J Am Soc Nephrol. 2014 Mar;25(3):431-42. doi: 10.1681/ASN.2013040361. Epub 2014 Jan 2. Review.

15.

Practical management of new oral anticoagulants after total hip or total knee arthroplasty.

Klauser W, Dütsch M.

Musculoskelet Surg. 2013 Dec;97(3):189-97. doi: 10.1007/s12306-013-0306-8. Epub 2013 Nov 19. Review.

16.

Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations.

Kinov P, Tanchev PP, Ellis M, Volpin G.

Int Orthop. 2014 Jan;38(1):169-75. doi: 10.1007/s00264-013-2134-8. Epub 2013 Oct 11. Review.

17.

Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.

Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, Carrier M.

BMJ. 2013 Aug 30;347:f5133. doi: 10.1136/bmj.f5133. Review.

18.

Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach.

Kittelson JM, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Steg G, Turpie AG, Cutler NR, Hiatt WR, Goldenberg NA; Antithrombotic Trials Leadership and Steering (ATLAS) Group.

J Thromb Haemost. 2013 Aug;11(8):1443-8. doi: 10.1111/jth.12324. Review.

19.

Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.

Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E, Rocha E.

Vasc Health Risk Manag. 2013;9:207-28. doi: 10.2147/VHRM.S35843. Epub 2013 May 8. Review.

20.

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.

Turpie AG, Schmidt AC, Kreutz R, Lassen MR, Jamal W, Mantovani L, Haas S.

Vasc Health Risk Manag. 2012;8:363-70. doi: 10.2147/VHRM.S30064. Epub 2012 Jun 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk